Revolution Medicines Inc. (RVMD): Price and Financial Metrics

Revolution Medicines Inc. (RVMD): $24.53

1.64 (-6.27%)

POWR Rating

Component Grades








Add RVMD to Watchlist
Sign Up

Industry: Biotech




#328 of 356

in industry

RVMD Price/Volume Stats

Current price $24.53 52-week high $35.50
Prev. close $26.17 52-week low $17.47
Day low $24.14 Volume 4,136,700
Day high $26.29 Avg. volume 1,142,328
50-day MA $30.37 Dividend yield N/A
200-day MA $26.11 Market Cap 2.68B

RVMD Stock Price Chart Interactive Chart >


  • Value is the dimension where RVMD ranks best; there it ranks ahead of 43.18% of US stocks.
  • The strongest trend for RVMD is in Growth, which has been heading down over the past 177 days.
  • RVMD's current lowest rank is in the Momentum metric (where it is better than 3.78% of US stocks).

RVMD Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for RVMD is 0.03 -- better than only 11.07% of US stocks.
  • Of note is the ratio of REVOLUTION MEDICINES INC's sales and general administrative expense to its total operating expenses; just 4.71% of US stocks have a lower such ratio.
  • With a price/sales ratio of 110.93, REVOLUTION MEDICINES INC has a higher such ratio than 97.98% of stocks in our set.
  • Stocks that are quantitatively similar to RVMD, based on their financial statements, market capitalization, and price volatility, are XBIT, IDYA, CRSP, NRIX, and ALPN.
  • Visit RVMD's SEC page to see the company's official filings. To visit the company's web site, go to

RVMD Valuation Summary

  • In comparison to the median Healthcare stock, RVMD's EV/EBIT ratio is 186.21% lower, now standing at -10.
  • RVMD's price/sales ratio has moved up 35.1 over the prior 44 months.

Below are key valuation metrics over time for RVMD.

Stock Date P/S P/B P/E EV/EBIT
RVMD 2023-09-22 110.9 3.5 -11.1 -10.0
RVMD 2023-09-21 112.7 3.6 -11.2 -10.1
RVMD 2023-09-20 109.9 3.5 -11.0 -9.9
RVMD 2023-09-19 114.6 3.6 -11.4 -10.3
RVMD 2023-09-18 114.4 3.6 -11.4 -10.3
RVMD 2023-09-15 117.4 3.7 -11.7 -10.6

RVMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RVMD has a Quality Grade of D, ranking ahead of 13.97% of graded US stocks.
  • RVMD's asset turnover comes in at 0.059 -- ranking 312th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows RVMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.059 1 -0.340
2021-03-31 0.068 1 -0.328
2020-12-31 0.083 1 -0.328
2020-09-30 0.107 1 -0.361
2019-12-31 0.256 1 -1.357

RVMD Price Target

For more insight on analysts targets of RVMD, see our RVMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $33.00 Average Broker Recommendation 1.57 (Moderate Buy)

Revolution Medicines Inc. (RVMD) Company Bio

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

RVMD Latest News Stream

Event/Time News Detail
Loading, please wait...

RVMD Latest Social Stream

Loading social stream, please wait...

View Full RVMD Social Stream

Latest RVMD News From Around the Web

Below are the latest news stories about REVOLUTION MEDICINES INC that investors may wish to consider to help them evaluate RVMD as an investment opportunity.

Insider Sell: COO Margaret Horn Sells 7,514 Shares of Revolution Medicines Inc (RVMD)

On September 18, 2023, Margaret Horn, the Chief Operating Officer (COO) of Revolution Medicines Inc (NASDAQ:RVMD), sold 7,514 shares of the company.

Yahoo | September 20, 2023

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

KRASG12D(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRASG12D mutation, the most common driver of RAS-addicted human cancers REDWOOD CITY, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-9805, an oral, co

Yahoo | September 19, 2023

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

Science Report on KRASG12C(ON)-Selective Inhibitors Provides Preclinical Proof-of-Principle for Company's RAS Innovation Engine and Broad Pipeline REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the publication of a peer-reviewed research paper in Science. This original research was led by scientists at Revolution Medicines and conducted in

Yahoo | August 17, 2023

Industry Analysts Just Made A Sizeable Upgrade To Their Revolution Medicines, Inc. (NASDAQ:RVMD) Revenue Forecasts

Revolution Medicines, Inc. ( NASDAQ:RVMD ) shareholders will have a reason to smile today, with the analysts making...

Yahoo | August 9, 2023

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -10.84% and 4.40%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 8, 2023

Read More 'RVMD' Stories Here

RVMD Price Returns

1-mo N/A
3-mo -6.37%
6-mo N/A
1-year 22.65%
3-year -31.00%
5-year N/A
YTD 2.98%
2022 -5.36%
2021 -36.42%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!